Posts Tagged analyst
Comindustria in downhill
While the indexes are floating above the line of equality the title Comindustria marks a loss of more than 4%. The title of the bank headed by Giuseppe Vigorelli it travels at a height loss of 8.11 euro 4.59%. “The title shares at a discount to its fair value but not to have consensus of the market,” says an analyst.
Related posts
Deutsche Bank honors the Swiss Novartis
Analysts at Deutsche Bank issued a positive opinion on the title of Swiss drugmaker Novartis. The advice is to buy with a target price of 75 Swiss Ranchi. Today the stocks traded on the Zurich Stock Exchange rising by 1, 92%, passing from hand to 63.55 Swiss francs.
Related posts
Gucci: a first quarter in line with expectations
The fashion house Gucci has published the results this morning for the first quarter of 2002, which revealed a decrease of 42% of net profit. A setback, however, expected by the market, and the result is placed in the bottom of the range estimated by analysts that follow the title. Lehman Brothers had issued an opinion of market perform on the title with a target price of 102 euros. Gucci, which is listed on the Amsterdam stock exchange, swap unchanged passing from hand to 100.30 euros.
Related posts
JP Morgan marketperform on Generali
JP Morgan reiterates its recommendation marketperform on Generali, with a target price of 32 euros. Analysts have noted positively the choice of generals to reorganize its operations in Italy bank insurance, which will result in cost savings and increased sales through the network of Understanding. Positive signals also came from the French market where it generally to the expectations sovraperfromato reporting a combined ratio (103.8%), inferior only to that of AGF and Axa. The EPS forecast by JP Morgan on 2002 is 1.05 euros, while in 2003 it was indicated at 1.2 euros.
Related posts
Paris: a few surprises among the titles biotech
At the Paris stock exchange sifting through the many titles in the list of Nouveau Marché technology may also find some pleasant surprises. One of these is the biotech industry, which after moments of true glory now seems to be out of fashion. In reality, the field of pharmaceutical biotechnology, as some analysts suggest, it seems more mature today than they were a couple of years ago. The same analysts, while advising caution, speak of the possibility to seize the opportunities of the licenses healthier financially in the long term. Paris seems to like, especially for its core, the title that Nicox YTD scored an increase of 12.52%. But the performance is certainly the most exciting +71.12% (YTD to date) of the title that has so Stallergenes recuparto part of the large slip scored last year. But continued to surf the net downward the former star of the field, particularly under the spotlight for having participated in the mapping of the human genome, Genset that from January 2002 has lost over 60% of its value. Oram the title that is worth less than three euros travels far from the peak at an altitude of 250 euros. A negative budget YTD for Cherep (-11.49%) even if the title stands today on the same level a year ago or so.
Related posts
Vodafone: good results, devaluation is not convincing
The British group Vodafone, the world number one in mobile communications, has announced the results of the financial year 2001-02 which were better than expectations, but analysts have crowded out with a mini-devaluation of its assets, making believe that most of the “writedown” will fall on the budget 2002-03. Adjusted EBITDA rose 44% to 10.1 billion pounds, surpassing the consensus of 9,8-9,9 billion pounds. The turnover stood at 29.8 billion pounds, has hit the market expectations that focused on 29,7-30 billion pounds. Vodafone said that back in the budget of 6 billion pounds as a provision, but these will not cover all the losses of value in their holdings. The writedown will cover subsidiaries Arcor, Cegetel, Japan Telecom, China Mobile and Grupo Iusacell. Analysts expected write-downs instead of between a minimum of 10 billion and a maximum of 25 billion, including assets acquired by Mannesmann in Italy and Germany. Vodafone has also introduced a double-digit growth in turnover for the current financial year.
Related posts
ABN Amro optimistic about new contract Unilever
The ABN Amro analyst Julian Hardwick appreciates the maxi-advertising agreement with Unilever to Granada and Carlton Communications. It does this because when interest rates are at their minimum levels, while the benefits could be substantial agreement. At this time, Unilever is traded in London at 636 pence (+0.6%), Carlton rises by 0.2% to 263.5 pence, while Granada yields 0.6% to 131.25 pence.
Related posts
Mib 30: Sanpaolo is no miracle
E ‘clearly negative weekly scorecard of the Sanpaolo-Imi, who left the field 10%. Sales on the title became abundant after the disclosure of quarterly results, which have not pleased the analysts. Compounding the situation, the passage of the package of shares in the hands of Sanpaolo Mps (equal to 5% of capital), sold to Bank Deusche to 11.2 euros.